Patient’s Perspectives of Experimental HCV-Positive to HCV-Negative Renal Transplantation: Report from a Single Site

Sarah E. Van Pilsum Rasmussen, Shanti Seaman, Diane Brown, Niraj Desai, Mark Sulkowski, Dorry L. Segev, Christine M. Durand, Jeremy Sugarman

Research output: Contribution to journalArticle

Abstract

Background: With growing transplant wait times, clinical trials are evaluating the safety and efficacy of transplanting HCV-infected donor (HCV+) organs into HCV-noninfected recipients (HCV D+/R-). Such transplants raise ethical questions about safety, consent, and access to organs. Methods: We interviewed eight of the ten total HCV D+/R- transplant recipients enrolled in a pilot clinical trial examining the safety and feasibility of these novel transplants regarding their experiences in the trial, including their decision-making and perceptions of the informed consent process. Results: All interviewees reported positive experiences and expressed confidence regarding their decision to participate. Participants accepted an HCV + organ based on their assessments of the risks and potential benefits of HCV D+/R- transplants. For many, the risks of HCV were minimal compared to the risks of not receiving a transplant. All participants recalled providing informed consent, reporting that the process was thorough and that all their questions were addressed. Participants did not regret receiving an HCV D+/R- transplant and did not report experiencing stigma. However, given their understanding of HCV cure rates in the general population and the survival benefit associated with kidney transplantation, participants may have conflated research regarding HCV D+/R- transplantation with clinical care, suggesting a potential therapeutic misconception. Conclusions: Recipients of experimental HCV D+/R- transplants generally seemed to recognize the risks and benefits of these novel transplants and did not regret participating. Such salutary reported experiences are important in assessing the appropriateness of further research into the feasibility of HCV D+/R- transplants.

Original languageEnglish (US)
JournalAJOB Empirical Bioethics
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Kidney Transplantation
Transplants
recipient
experience
Informed Consent
Safety
Therapeutic Misconception
confidence
Emotions
decision making
Clinical Trials
Transplantation
Research
Decision Making
Tissue Donors
Survival
Recipient
Organs
Population

Keywords

  • hepatitis C
  • interview
  • qualitative research
  • research ethics
  • Transplantation

ASJC Scopus subject areas

  • Health(social science)
  • Philosophy
  • Health Policy

Cite this

@article{a7e5056041b84d138d1d8991dc6dbd72,
title = "Patient’s Perspectives of Experimental HCV-Positive to HCV-Negative Renal Transplantation: Report from a Single Site",
abstract = "Background: With growing transplant wait times, clinical trials are evaluating the safety and efficacy of transplanting HCV-infected donor (HCV+) organs into HCV-noninfected recipients (HCV D+/R-). Such transplants raise ethical questions about safety, consent, and access to organs. Methods: We interviewed eight of the ten total HCV D+/R- transplant recipients enrolled in a pilot clinical trial examining the safety and feasibility of these novel transplants regarding their experiences in the trial, including their decision-making and perceptions of the informed consent process. Results: All interviewees reported positive experiences and expressed confidence regarding their decision to participate. Participants accepted an HCV + organ based on their assessments of the risks and potential benefits of HCV D+/R- transplants. For many, the risks of HCV were minimal compared to the risks of not receiving a transplant. All participants recalled providing informed consent, reporting that the process was thorough and that all their questions were addressed. Participants did not regret receiving an HCV D+/R- transplant and did not report experiencing stigma. However, given their understanding of HCV cure rates in the general population and the survival benefit associated with kidney transplantation, participants may have conflated research regarding HCV D+/R- transplantation with clinical care, suggesting a potential therapeutic misconception. Conclusions: Recipients of experimental HCV D+/R- transplants generally seemed to recognize the risks and benefits of these novel transplants and did not regret participating. Such salutary reported experiences are important in assessing the appropriateness of further research into the feasibility of HCV D+/R- transplants.",
keywords = "hepatitis C, interview, qualitative research, research ethics, Transplantation",
author = "{Van Pilsum Rasmussen}, {Sarah E.} and Shanti Seaman and Diane Brown and Niraj Desai and Mark Sulkowski and Segev, {Dorry L.} and Durand, {Christine M.} and Jeremy Sugarman",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/23294515.2019.1670277",
language = "English (US)",
journal = "AJOB Empirical Bioethics",
issn = "2329-4515",
publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - Patient’s Perspectives of Experimental HCV-Positive to HCV-Negative Renal Transplantation

T2 - Report from a Single Site

AU - Van Pilsum Rasmussen, Sarah E.

AU - Seaman, Shanti

AU - Brown, Diane

AU - Desai, Niraj

AU - Sulkowski, Mark

AU - Segev, Dorry L.

AU - Durand, Christine M.

AU - Sugarman, Jeremy

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: With growing transplant wait times, clinical trials are evaluating the safety and efficacy of transplanting HCV-infected donor (HCV+) organs into HCV-noninfected recipients (HCV D+/R-). Such transplants raise ethical questions about safety, consent, and access to organs. Methods: We interviewed eight of the ten total HCV D+/R- transplant recipients enrolled in a pilot clinical trial examining the safety and feasibility of these novel transplants regarding their experiences in the trial, including their decision-making and perceptions of the informed consent process. Results: All interviewees reported positive experiences and expressed confidence regarding their decision to participate. Participants accepted an HCV + organ based on their assessments of the risks and potential benefits of HCV D+/R- transplants. For many, the risks of HCV were minimal compared to the risks of not receiving a transplant. All participants recalled providing informed consent, reporting that the process was thorough and that all their questions were addressed. Participants did not regret receiving an HCV D+/R- transplant and did not report experiencing stigma. However, given their understanding of HCV cure rates in the general population and the survival benefit associated with kidney transplantation, participants may have conflated research regarding HCV D+/R- transplantation with clinical care, suggesting a potential therapeutic misconception. Conclusions: Recipients of experimental HCV D+/R- transplants generally seemed to recognize the risks and benefits of these novel transplants and did not regret participating. Such salutary reported experiences are important in assessing the appropriateness of further research into the feasibility of HCV D+/R- transplants.

AB - Background: With growing transplant wait times, clinical trials are evaluating the safety and efficacy of transplanting HCV-infected donor (HCV+) organs into HCV-noninfected recipients (HCV D+/R-). Such transplants raise ethical questions about safety, consent, and access to organs. Methods: We interviewed eight of the ten total HCV D+/R- transplant recipients enrolled in a pilot clinical trial examining the safety and feasibility of these novel transplants regarding their experiences in the trial, including their decision-making and perceptions of the informed consent process. Results: All interviewees reported positive experiences and expressed confidence regarding their decision to participate. Participants accepted an HCV + organ based on their assessments of the risks and potential benefits of HCV D+/R- transplants. For many, the risks of HCV were minimal compared to the risks of not receiving a transplant. All participants recalled providing informed consent, reporting that the process was thorough and that all their questions were addressed. Participants did not regret receiving an HCV D+/R- transplant and did not report experiencing stigma. However, given their understanding of HCV cure rates in the general population and the survival benefit associated with kidney transplantation, participants may have conflated research regarding HCV D+/R- transplantation with clinical care, suggesting a potential therapeutic misconception. Conclusions: Recipients of experimental HCV D+/R- transplants generally seemed to recognize the risks and benefits of these novel transplants and did not regret participating. Such salutary reported experiences are important in assessing the appropriateness of further research into the feasibility of HCV D+/R- transplants.

KW - hepatitis C

KW - interview

KW - qualitative research

KW - research ethics

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=85074327441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074327441&partnerID=8YFLogxK

U2 - 10.1080/23294515.2019.1670277

DO - 10.1080/23294515.2019.1670277

M3 - Article

C2 - 31618112

AN - SCOPUS:85074327441

JO - AJOB Empirical Bioethics

JF - AJOB Empirical Bioethics

SN - 2329-4515

ER -